WeChat· 石药集团·· 1 day agoPickScore86
CSPC's HD1916 Meets Equivalence to Wegovy in Phase 3 Obesity Trial Published in Diabetes, Obesity and Metabolism
In brief
CSPC Pharmaceutical Group's HD1916, a chemically synthesized semaglutide injection, showed therapeutic equivalence to Wegovy in a Phase 3 obesity study published in Diabetes, Obesity and Metabolism (PMID: 42839752). The trial met its prespecified equivalence margin for weight loss versus the comparator.
Why it matters
The paper provides 44-week weight change, equivalence margin, and adverse event data for direct comparison of HD1916 and Wegovy.
Source: WeChat · mp.weixin.qq.com